Focusing on patient-centered care, Rana R. McKay, MD, and the Oncology Brothers discuss the role of PSA and PSMA PET scans in guiding treatment for patients with prostate cancer.
BCRFS Seen With Apalutamide Combo in Entire High-Risk Prostate Cancer Group
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.
Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.
HIFU Yields Noninferior Outcomes Vs Prostatectomy in Local Prostate Cancer
Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.
Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer
Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
Taplin’s Key to a Successful GU Career: “Always Finish” What You Start
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
EU’s CHMP Recommends Enzalutamide Approval in Non-Metastatic HSPC
The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.